Head-to-head · WeighScore
AlyveRx vs FlyteHealth
The verdict
AlyveRx takes it — 70.5/100 to 58.6/100.
AlyveRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AlyveRx (Alyve, Inc.) is a US online telehealth platform connecting patients with licensed providers for GLP-1 weight loss care, no insurance required, with free discreet delivery.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AlyveRx | FlyteHealth |
|---|---|---|
| WeighScore | 70.5/100 | 58.6/100 |
| Grade | C | C |
| Scorecard rank | #103 | #364 |
| Semaglutide | $183/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $249/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #103 · C
Strengths
- Offers compounded semaglutide and tirzepatide as both injections and needle-free sublingual drops for people who dislike needles
- Transparent monthly pricing shown upfront, no insurance required, and free discreet delivery
- Also carries brand-name Ozempic, Wegovy, and Mounjaro through its provider network
Where it loses points
- Does not publicly name its dispensing pharmacy or display a LegitScript seal, so third-party accreditation is unverified
- Sublingual GLP-1 absorption relies on the company proprietary PermeAct technology and is not FDA-reviewed for weight loss
- State availability is not published on the site
Graded #364 · C
Strengths
- Care led by board-certified obesity-medicine physicians
- Multidisciplinary team with NPs, dietitians, and care coordinators
- Published outcomes of about 13 to 16 percent weight loss over 12 months
- High GLP-1 medication adherence (around 86 percent in reported data)
- Comprehensive cardiometabolic care beyond GLP-1 alone
Where it loses points
- Distributed primarily via employers, payers, and health plans, not direct cash-pay
- Access is largely gated behind employer or plan sponsorship
- GLP-1 is prescribed only when appropriate, not guaranteed
- Self-pay pricing is not publicly listed (contact required)
- Less suited to consumers wanting fast direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.